Jasper Therapeutics, Inc. Annual Report: A Plain-English Guide

This guide breaks down Jasper Therapeutics’ performance over the past year. My goal is to translate complex filings into simple terms to help you decide if this company fits your investment strategy.

1. What does this company do?

Jasper is a biotech company in the testing phase. They do not sell products yet, so they have no sales revenue. They focus on "mast cell-driven diseases," such as chronic hives and asthma. Their lead drug, briquilimab, acts like a reset button. It targets specific cells to stop the chronic inflammation that causes these conditions.

2. Major wins and challenges

The company is currently running three main clinical trials:

• The BEACON Study (Hives): This is their main study. After investigating inconsistencies in patient selection at certain sites in mid-2025, the company tightened its rules. Data from 2026 shows that patients taking briquilimab now see a significant reduction in itching compared to those taking a placebo.
• The SPOTLIGHT Study (Cold Hives): This study shows strong results. In recent data, 96% of participants improved. Notably, 88% of those on the highest dose saw their hives disappear completely during cold-exposure tests.
• The ETESIAN Study (Asthma): This study proved that briquilimab reduces airway inflammation in asthma patients. This success indicates the drug could potentially work for millions of people beyond those with skin conditions.

3. Financial health

Jasper is currently spending more than it earns. In 2025, the company lost about $85 million, with $65 million dedicated to research and development. They ended the year with roughly $140 million in cash. To preserve capital, they discontinued their older stem cell transplant programs in July 2025. This allows them to fund operations through the second half of 2027 while focusing exclusively on the mast cell program.

4. Key risks

Biotech investing is inherently volatile, and Jasper’s value depends heavily on the success of a single drug.

• Concentration Risk: Because the company relies on one primary drug, any negative feedback from the FDA or poor future test results could significantly impact the company's valuation.
• Share Dilution: Without product revenue, the company must sell more shares to raise capital. This typically decreases the ownership percentage of existing shareholders.
• Regulatory Hurdles: The FDA may require larger, more expensive trials than currently planned. This would increase cash burn and potentially accelerate the need for additional stock offerings.

5. Future outlook

Jasper is positioning itself to become a full-scale drug company. They are preparing for a large Phase 2b/3 study for chronic hives, which will be the primary driver of their value over the next 18 months. Success hinges on maintaining cash reserves through 2027, meeting strict FDA safety standards, and potentially securing a partnership with a larger pharmaceutical company to help manage the costs of commercialization.

---

Investor Takeaway: Jasper is a high-risk, high-reward play. You are essentially betting on the success of one drug, briquilimab. If you are considering an investment, watch their upcoming Phase 2b/3 trial results closely, as these will be the most important indicators of whether the company can successfully bring a product to market.